WO2011032929A1 - (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability - Google Patents
(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability Download PDFInfo
- Publication number
- WO2011032929A1 WO2011032929A1 PCT/EP2010/063439 EP2010063439W WO2011032929A1 WO 2011032929 A1 WO2011032929 A1 WO 2011032929A1 EP 2010063439 W EP2010063439 W EP 2010063439W WO 2011032929 A1 WO2011032929 A1 WO 2011032929A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- acid
- pharmaceutical composition
- solid pharmaceutical
- composition according
- Prior art date
Links
- UTNUDOFZCWSZMS-YFHOEESVSA-N C/C(/O)=C(/C(Nc1ccc(C(F)(F)F)cc1)=O)\C#N Chemical compound C/C(/O)=C(/C(Nc1ccc(C(F)(F)F)cc1)=O)\C#N UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to pharmaceutical compositions comprising (Z)-2- cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide, commonly known as Teriflunomide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease or multiple sclerosis or rheumatoid arthritis.
- compositions useful for treating autoimmune diseases in particular lupus erythematosus disclose compositions useful for treating autoimmune diseases in particular lupus erythematosus.
- Teriflunomide has been shown to produce antiproliferative effects on a wide variety of immune cells and cell lines (Cherwinski H. M., et al., J Pharmacol. Exp. Ther. 1995;272:460-8; Prkash A., et al., Drugs 1999;58(6):1 137-66; Bartlett R. R. et al., Agent Action 1991 ;32(1 -2):10-21 ).
- European Patent 1381356 B1 discloses the use of Teriflunomide for the manufacture of a medicament for treating multiple sclerosis wherein said medicament is administered orally.
- a solid pharmaceutical formulation for Teriflunomide was developed for use in clinical studies.
- One of the observations made during stability studies was a strong increase in one degradant, which is 2-cyano-N-(4-trifluoromethyl-phenyl)-acetamide and has the str ture illustrated in Formula II:
- the present invention is a solid pharmaceutical composition
- a solid pharmaceutical composition comprising about 1 % to 30 % weight: weight (w: w) Teriflunomide, or a pharmaceutically acceptable basic addition salt thereof, about 5 % to 20 % weight: weight disintegrant, about 0 % to 40 % weight: weight binder, about 0.1 % to 2 % weight: weight lubricant and the remaining percentage comprising diluents provided that said solid pharmaceutical composition does not contain colloidal silicon dioxide.
- a second aspect of the invention is a solid pharmaceutical composition
- a solid pharmaceutical composition comprising about 1 % to 20 % weight: weight Teriflunomide, or a pharmaceutically acceptable basic addition salt thereof, about 5 % to 20 % weight: weight disintegrant, about 0 % to 30 % weight: weight binder, about 0.1 % to 2 % weight: weight lubricant, about 1 % to 20 % weight: weight acidic reacting compound and the remaining percentage comprising diluents.
- a third aspect of the invention is a solid pharmaceutical composition
- a solid pharmaceutical composition comprising about 1 % to 20 % weight: weight Teriflunomide, or a pharmaceutically acceptable basic addition salt thereof, about 5 % to 20 % weight: weight disintegrant, about 0 % to 30 % weight: weight binder, about 0.1 % to 2 % weight: weight lubricant, about 1 % to 20 % weight: weight acidic reacting compound, about 0,1 % to 0.5 % weight: weight colloidal silicon dioxide and the remaining percentage comprising diluents.
- the preparation according to the invention therefore provides a solid pharmaceutical composition
- a solid pharmaceutical composition comprising
- said solid pharmaceutical composition does not contain colloidal silicon dioxide.
- Colloidal silicon dioxide is submicroscopic fumed silica, also known as pyrogenic silica. It is a non-crystalline, fine grain, low density and high surface area silica. Primary particle size is from 5 nm to 50 nm. The particles are non-porous and have a surface from 50 m 2 /g to 600 m 2 /g. It can be obtained for example under the trade name Aeorsil 200 Pharma from Evonik Industries [Evonik Degussa GmbH, Inorganic Materials, 9, 60287 Frankfurt, Germany] or under the trade name CAB-O-SIL M-5P/5DP Cabot Corporation headquartered at Boston, Massachusetts, U.S.A.
- Degradant refers to any drug-based materials generated after the preparation of the unit dosage form. Analysis of impurities and degradant is done using reverse phase HPLC techniques on extracted samples as is known in the art.
- “Pharmaceutically acceptable basic addition salt” is any non-toxic organic or inorganic basic addition salt of the compound Teriflunomide.
- Illustrative inorganic bases which form suitable salts include potassium hydroxide, sodium hydroxide, L- lysine or calcium hydroxide.
- "Patient” means a warm blooded animal, such as for example rat, mice, dogs, cats, guinea pigs, and primates such as humans.
- Treating means any treatment, including, but not limited to, alleviating symptoms, eliminating the causation of the symptoms either on a temporary or permanent basis, or preventing or slowing the appearance of symptoms and
- “Therapeutically effective amount” means an amount of the compound, which is effective in treating the named disorder or condition.
- Stepoisomers is a general term for all isomers of the individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereoisomers).
- Teriflunomide is the generic name for the compound (Z)-2-cyano-3-hydroxy- but-2-enoic acid-(4'-trifluoromethylphenyl)-amide.
- Teriflunomide can be used in the form in which it is chemically prepared, or it can be subjected to a process which changes the physical nature of the particles.
- the material can be milled by any process known in the art. Non exclusive examples of such processes include mechanical milling and jet milling.
- the particles produced either directly from the process of chemically preparing Teriflunomide or after a milling operation preferably provide average particle diameters in the range of 1 ⁇ to 100 ⁇ . It is advantageous to use said Teriflunomide particles from 1 ⁇ to 100 ⁇ in the preparation of the solid pharmaceutical composition, especially at about 1 % to 10 % weight: weight of
- Teriflunomide has been disclosed, and is accomplished by methods that are well known to those skilled in the art.
- US Patent 5,990,141 issued on November 23, 1999 discloses methods of synthesis.
- the invention relates to a solid pharmaceutical composition comprising from about 2 % to 15 % weight: weight Teriflunomide and the other components disintegrant, binder, lubricant and diluents show the same amount as defined under b) to e) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 7 % to 15 % weight: weight disintegrant and the other components Teriflunomide, binder, lubricant and diluents show the same amount as defined under a) and c) to e) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 15 % to 35 % weight: weight binder and the other components Teriflunomide, disintegrant, lubricant and diluents show the same amount as defined under a), b), d) and e) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 0,1 % to 1 ,0 % weight: weight lubricant and the other components Teriflunomide, disintegrant, binder and diluents show the same amount as defined under a) to c) and e) above.
- disintegrants are carboxymethylcellulose, low substituted hydroxyproyl cellulose, microcrystalline cellulose, powdered cellulose, croscarmellose sodium, methylcellulose, polacrilin potassium, sodium alginate, sodium starch glycolate or a mixture of one or more of said disintegrants.
- binders are acacia, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, dextrin, gelatin, guar gum, hydroxypropyl methylcellulose, maltodextrin, methylcellulose, sodium alginate, pregelatinized starch, starches such as potato starch, corn starch or cereal starch and zein or a mixture of one or more of said binders.
- lubricants are calcium stearate, glyceryl palmitostearate, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate and magnesium stearate or a mixture of one or more of said lubricants.
- diluents examples include cellulose, cellulose acetate, dextrates, dextrin, dextrose, fructose, 1 -O-a-D-Glucopyranosyl-D-mannitol, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, lactose, lactose mono-hydrate, maltitol, mannitol, maltodextrin, maltose, pregelatinized starch, sodium chloride, sorbitol, starches, sucrose, talc and xylitol or a mixture of one or more of said diluents.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from 2 % to 15 % weight: weight Teriflunomide, 7 % to 15 % weight: weight disintegrant selected from one or more of microcrystalline cellulose or sodium starch glycolate, 15 % to 35 % weight: weight binder selected from one or more of hydroxyproylcellulose or corn starch, 0,1 % to 1 ,0 % weight: weight lubricant selected from magnesium stearate and the remaining percentage comprising diluents selected from lactose mono-hydrate.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 2 % to 15 % weight: weight Teriflunomide and the other components disintegrant, binder, lubricant, acidic reacting compound and diluents show the same amount as defined under B) to F) above.
- a solid pharmaceutical composition comprising from about 7 % to 15 % weight: weight disintegrant and the other components Teriflunomide, binder, lubricant, acidic reacting compound and diluents show the same amount as defined under A) and C) to F) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 15 % to 30 % weight: weight binder and the other components Teriflunomide, disintegrant, lubricant, acidic reacting compound and diluents show the same amount as defined under A), B) and D) to F) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 0,1 % to 1 ,0 % weight: weight lubricant and the other components Teriflunomide, disintegrant, binder, acidic reacting compound and diluents show the same amount as defined under A) to C), E and F) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 3 % to 20 % weight: weight acidic reacting compound and the other components Teriflunomide, disintegrant, binder, lubricant and diluents show the same amount as defined under A) to D) and F) above.
- acidic reacting compound examples include citric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, benzoic acid,
- Teriflunomide is mixed with said disintegrant, binder, lubricant and diluents constituents to obtain the concentration of Teriflunomide and said further components according to the present invention in the final mixture and finally is mixed with an acidic reacting compound.
- the solid pharmaceutical composition comprising components A) to F) as defined above shows a pH from 4.5 to 2.0, when water is adsorbed to the pharmaceutical composition or when water is added in small amounts to the pharmaceutical composition.
- the solid pharmaceutical composition comprising components A) to F) as defined above shows a pH from about pH 3 to about pH 2.
- the pH determination is performed by suspending one tablet in about 1 ml of purified water.
- the pH of the supernatant is determined with a pH sensitive probe.
- the invention relates to a solid pharmaceutical composition comprising
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 2 % to 15 % weight: weight Teriflunomide and the other components disintegrant, binder, lubricant, acidic reacting compound, colloidal silicon dioxide and diluents show the same amount as defined under B) to G) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 7 % to 15 % weight: weight disintegrant and the other components Teriflunomide, binder, lubricant, acidic reacting compound, colloidal silicon dioxide and diluents show the same amount as defined under A) and C) to G) above.
- a solid pharmaceutical composition comprising from about 15 % to 30 % weight: weight binder and the other components Teriflunomide, disintegrant, lubricant, acidic reacting compound, colloidal silicon dioxide and diluents show the same amount as defined under A), B) and D) to G) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 0,1 % to 1 ,0 % weight: weight lubricant and the other components Teriflunomide, disintegrant, binder, acidic reacting compound, colloidal silicon dioxide and diluents show the same amount as defined under A) to C), E and G) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 3 % to 20 % weight: weight acidic reacting compound and the other components Teriflunomide, disintegrant, binder, lubricant, colloidal silicon dioxide and diluents show the same amount as defined under A) to D) and F) and G) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 0.2 % to 0.4 % weight: weight colloidal silicon dioxide and the other components Teriflunomide, disintegrant, binder, lubricant, acidic reacting compound and diluents show the same amount as defined under A) to E) and G) above.
- the invention relates to a solid pharmaceutical composition
- a solid pharmaceutical composition comprising from about 0.3 % weight: weight colloidal silicon dioxide and the other components Teriflunomide, disintegrant, binder, lubricant, acidic reacting compound and diluents show the same amount as defined under A) to E) and G) above.
- Teriflunomide is mixed with said disintegrant, binder, lubricant, colloidal silicon dioxide and diluents constituents to obtain the concentration of Teriflunomide and said further components according to the present invention in the final mixture and finally is mixed with an acidic reacting compound.
- the solid pharmaceutical composition comprising components A) to G) as defined above shows a pH from 4.5 to 2.0, when water is adsorbed to the pharmaceutical
- the solid pharmaceutical composition comprising components A) to G) as defined above shows a pH from about pH 3 to about pH 2.
- the Teriflunomide and the further components of the solid pharmaceutical composition according to the invention can be mixed as powders.
- This mixing can be carried out using any of the mixing techniques known in the art.
- the mixing is preferably carried out using a high shear mixer, V-blender (or other twin-shell blender), bin blender or Turbula mixer-shaker. Blending is typically carried out first without the addition of a lubricant for sufficient time to assure complete mixing. At that point, the lubricant is typically added followed by a short (about 1 -10 minute) further mixing period.
- unit dosage forms are prepared by procedures known in the art. Preferably, unit dosage forms are made on rotary tablet presses or capsule filling machines. The dosage forms thus prepared can then optionally be coated with a film designed to provide ease of swallowing, a proprietary or identification appearance and/or protection of the dosage form.
- Teriflunomide and the further components of the solid pharmaceutical composition comprise the following steps:
- step (b) adding a granulation solvent while the material from step (a) is under shear.
- Preferred granulation solvents include, water, ethanol, isopropanol and combinations thereof. Other ingredients can be added to the granulation solvent as known in the art. Examples of such additives are binders, acidic reacting compounds, wetting agents, stabilizers and buffers.
- the solvent can be applied by any technique known in the art. Preferred methods of applying the solvent while imparting shear include high shear granulation, low shear granulation, fluid bed granulation and extrusion granulation;
- step (c) optionally, the material from step (b) can be milled, ground or sieved.
- This wet material is then dried, preferably using air drying, fluid bed drying, oven drying or microwave drying.
- the drying is preferably carried out such that the drying temperature does not exceed about 60°C;
- composition is optionally formed into a unit dosage form
- a tablet or a capsule preferably a tablet or a capsule.
- the dosage forms thus prepared can then optionally be coated with a film designed to provide ease of swallowing, a proprietary or identification appearance and/or protection of the dosage form.
- the packaging is preferably in the form of foil-foil cold form blisters, plastic blisters or sealed bottles with or without desiccant.
- packaging materials with a water vapor permeability below 0.25 g/m 2 /day are preferred.
- the solid pharmaceutical composition according to the invention can be administered in any form or mode which makes the compound bioavailable in therapeutically effective amounts, including orally, sublingually, buccally,
- the solid pharmaceutical composition according to the invention may be administered orally, for example, in the form of tablets, troches, capsules, wafers, chewing gums and the like.
- Other dosage unit forms may contain other various materials, which modify the physical form of the dosage unit, for example, as coatings.
- tablets or pills may be coated with nonfunctional coatings like Hypromelose based coatings, sugar, shellac, or other enteric coating agents.
- Teriflunomide will exhibit their therapeutic activities at dosages of between about 0.001 mg/kg of patient body weight/day to about 100 mg/kg of patient body weight/day.
- the solid pharmaceutical composition according to the invention is suitable for example, for treating acute immunological events, such as sepsis, allergy, graft- versus-host- reactions and host-versus-graft-reactions, Autoimmune disease such as rheumatoid arthritis, systemic lupus erythematodes, or multiple sclerosis, psoriasis, asthma, urticaria, rhinitis and uveitis, cancerous diseases such as lung cancer, leukemia, ovarian cancer, sarcoma, Kaposi's sarcoma, meningioma, intestinal cancer, lymph node cancer, brain tumours, breast cancer, pancreatic cancer, prostate cancer or skin cancer.
- acute immunological events such as sepsis, allergy, graft- versus-host- reactions and host-versus-graft-reactions, Autoimmune disease such as rheumatoid arthritis, systemic lupus erythematodes, or multiple sclerosis,
- HPC Hydroxypropyl cellulose 7.5 mPa * s (HPC) and Citric acid monohydrate are dissolved in 219.3 g of purified water and are stirred for at least 30 min.
- the concentration of HPC in the final solution is 6.4% relative to the mass of water irrespective of the amount of citric acid added, (table 1 ).
- the resulting blend is granulated with a solution of HPC and if necessary citric acid in a fluid bed granulator (UNI Glatt, flap 25-30%, inlet air temperature 60°C, shaking interval 60 sec, shaking 5 sec, spray rate ⁇ 12.5g/min, atomizing air pressure 1 bar, nozzle diameter 0.8 mm). Duration approx. 25 min 3.
- the granules are dried in a fluid bed granulator for approx. 20 min (UNI Glatt, flap 25-30%, inlet air temperature 60°C, shaking interval 60 sec, shaking 5 sec). 4.
- the granules are calibrated through a 1 mm sieve and are lubricated with microcrystalline cellulose, sodium starch glycollate and if necessary with colloidal silicon dioxide (Examples 1 F - 1 J) in a turbula blender [2 L glass container] for 5 min. 5. After addition of Magnesium stearate the mixture is blended for another minute in a turbula blender [2 L glass container].
- the final blend is compressed to tablets on a Korsch EKO single punch press.
- composition of the solid pharmaceutical compositions prepared is given in tables 1 , 2 and 3.
- composition of Teriflunomide tablets acidified with citric acid and with colloidal silicon dioxide
- the tablets are prepared according to the manufacturing process given in example 1 .
- the composition of the tablets is given in tables 1 , 2 and 3. Storage of the Tablets
- the samples are stored for up to 6 months at 25°C/60%RH, 30°C/65%RH,
- Tablets are analyzed for content by HPLC.
- RH means relative humidity; the relative humidity of an air-water mixture is defined as the ratio of the partial pressure of water vapor in the mixture to the saturated vapor pressure of water at a prescribed temperature.
- Teriflunomide tablets containing 25 mg citric acid lubricated with or without colloidal silicon dioxide [Examples 1 C, D, I, J] and Teriflunomide tablets containing no citric acid but lubricated without colloidal silicon dioxide (Example OA) display significantly reduced formation of 2-cyano-N-(4-trifluoromethyl-phenyl)-acetamide compared to Teriflunomide tablets containing colloidal silicon dioxide (Example 0B).
- the stabilizing effect of citric acid is more pronounced in the presence of colloidal silicon dioxide.
- Buffer is prepared by the transfer of 50 mmol (4.2 g) of sodium acetate, 50 mmol (2.9 g) of sodium chloride in a glass bottle for mobile phases and addition of 1000 mL water. Adjust pH to 6.5 with glacial acetic acid using a pH-meter.
- Mobile phase A Mobile phase B
- Buffer pH 6.5 900 mL Buffer pH 6.5 100 mL
- Auto sampler temperature Set auto sampler temperature at
- the pH determination is performed by suspending one tablet in about 1 ml of purified water. After disintegration of the tablet and settling of the solid contents, the pH of the supernatant is determined with a pH sensitive probe. The mean result of two individual tablets is reported as pH of tablet (see tables 2 and 3).
- the tablets are prepared according to the manufacturing process given in example 1 .
- the composition of the tablets is given in table 1 .
- samples are stored for 6 months at 40°C/75%RH in induction sealed HDPE bottles [wide necked bottle, 60 mL, white, round with induction seal and child resistant screw cap]. Bottles are stored upright.
- Tablets are analyzed for related impurities by HPLC (using the method described above).
- Teriflunomide tablets lubricated without colloidal silicon dioxide display significantly reduced formation of 2-cyano-N-(4-trifluoromethyl-phenyl)- acetamide compared to Teriflunomide tablets containing colloidal silicon dioxide (Example 0B and 0C).
- 4-TFMA is strongly reduced in tablets containing no colloidal silicon dioxide (Example OA and 0D) compared to tablets lubricated with colloidal silicon dioxide ((Example 0B and 0C).
- the determination of Teriflunomide and 2-cyano-N-(4-trifluoromethyl-phenyl)- acetamide and 4-TFMA are performed by a gradient high performance liquid chromatographic system (HPLC) as described in Example 2.
Abstract
Description
Claims
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2772275A CA2772275A1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
RS20170589A RS56074B1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
NZ598744A NZ598744A (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
AU2010297357A AU2010297357B2 (en) | 2009-09-18 | 2010-09-14 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
EP10752585.9A EP2477611B1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
BR112012006184-4A BR112012006184B1 (en) | 2009-07-12 | 2010-09-14 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4-TRIFLUORMETHYLPHENYL)-AMIDE ACID |
MX2012003122A MX336663B (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)- amide tablet formulations with improved stability. |
JP2012529234A JP2013505213A (en) | 2009-09-18 | 2010-09-14 | (Z) -2-Cyano-3-hydroxy-but-2-enoic acid- (4'-trifluoromethylphenyl) -amide tablet formulation with improved stability |
DK10752585.9T DK2477611T3 (en) | 2009-09-18 | 2010-09-14 | (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY |
KR1020127006940A KR101547880B1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
MEP-2017-134A ME02765B (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
CR20170078A CR20170078A (en) | 2009-09-18 | 2010-09-14 | FORMULATIONS IN COMMITMENT OF THE (4-TRIFLUOROMETILFENIL) AMIDA OF THE ACID (Z) -2-CIANO-3-HYDROXIBUTE-2-ENOICO WITH IMPROVED STABILITY |
US13/395,586 US20120172427A1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
CN201080041529.8A CN102596184B (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
RU2012115459/15A RU2012115459A (en) | 2009-09-18 | 2010-09-14 | TABLETABLE MEDICINE (4'-TRIFFORMETHYLPHENYL) AMID (Z) -2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID WITH IMPROVED STABILITY |
LTEP10752585.9T LT2477611T (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4`-trifluormethylphenyl)-amide tablet formulations with improved stability |
UAA201204827A UA107582C2 (en) | 2009-09-18 | 2010-09-14 | TABLETTED PREPARATION (4'-Trifluoromethylphenyl) AMIDE (Z) -2-cyano-hydroxybut-2-enoic acid with improved resistance |
ES10752585.9T ES2625731T3 (en) | 2009-09-18 | 2010-09-14 | Tablet formulations of 2-cyano-3-hydroxy-but-2-enoic acid (Z) - (4 ¿-trifluoromethylphenyl) -amide with improved stability |
SI201031476A SI2477611T1 (en) | 2009-09-18 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
TNP2012000061A TN2012000061A1 (en) | 2009-09-18 | 2012-02-10 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
IL218492A IL218492A (en) | 2009-09-18 | 2012-03-05 | (z)-2-cyano-3-hydroxy-but-3-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
MA34687A MA33585B1 (en) | 2009-09-18 | 2012-03-13 | (Z) -2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID (4'-TRIFLUOROMETHYLPHENYL) -AMIDE TABLET FORMULATIONS WITH IMPROVED STABILITY |
US13/422,494 US8802735B2 (en) | 2009-09-18 | 2012-03-16 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
US14/265,433 US20140235888A1 (en) | 2009-09-18 | 2014-04-30 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
IL244809A IL244809B (en) | 2009-09-18 | 2016-03-28 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
US15/290,677 US20170247319A1 (en) | 2009-09-18 | 2016-10-11 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
HRP20170904TT HRP20170904T1 (en) | 2009-09-18 | 2017-06-13 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability |
CY20171100710T CY1119364T1 (en) | 2009-09-18 | 2017-07-04 | PHARMACEUTICAL FORMS (G) -2-KYANO-3-HYDROXY-BUT-2-ENOIC ACID- (4'-TRIFFluoromethylphenyl) -AMIDE WITH IMPROVED |
US15/999,565 US20190241505A1 (en) | 2009-09-18 | 2018-08-20 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
IL26491219A IL264912B (en) | 2009-09-18 | 2019-02-19 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/363,382 | 2009-07-12 | ||
EP09290716 | 2009-09-18 | ||
EP09290716.1 | 2009-09-18 | ||
US36338210P | 2010-07-12 | 2010-07-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/422,494 Continuation-In-Part US8802735B2 (en) | 2009-09-18 | 2012-03-16 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011032929A1 true WO2011032929A1 (en) | 2011-03-24 |
Family
ID=41510564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/063439 WO2011032929A1 (en) | 2009-07-12 | 2010-09-14 | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Country Status (40)
Country | Link |
---|---|
US (5) | US20120172427A1 (en) |
EP (1) | EP2477611B1 (en) |
JP (1) | JP2013505213A (en) |
KR (1) | KR101547880B1 (en) |
CN (4) | CN104666238B (en) |
AR (1) | AR078383A1 (en) |
AU (2) | AU2010297357B2 (en) |
BR (1) | BR112012006184B1 (en) |
CA (1) | CA2772275A1 (en) |
CL (1) | CL2015000047A1 (en) |
CO (1) | CO6511244A2 (en) |
CR (2) | CR20170078A (en) |
CY (1) | CY1119364T1 (en) |
DK (1) | DK2477611T3 (en) |
DO (1) | DOP2012000070A (en) |
ES (1) | ES2625731T3 (en) |
GT (1) | GT201200075A (en) |
HK (2) | HK1206245A1 (en) |
HN (1) | HN2012000576A (en) |
HR (1) | HRP20170904T1 (en) |
HU (1) | HUE032963T2 (en) |
IL (3) | IL218492A (en) |
JO (1) | JO3327B1 (en) |
LT (1) | LT2477611T (en) |
MA (1) | MA33585B1 (en) |
ME (1) | ME02765B (en) |
MX (1) | MX336663B (en) |
MY (1) | MY155613A (en) |
NZ (2) | NZ598744A (en) |
PE (2) | PE20121478A1 (en) |
PL (1) | PL2477611T3 (en) |
PT (1) | PT2477611T (en) |
RS (1) | RS56074B1 (en) |
RU (2) | RU2012115459A (en) |
SI (1) | SI2477611T1 (en) |
TN (1) | TN2012000061A1 (en) |
TW (2) | TWI468190B (en) |
UA (2) | UA107582C2 (en) |
UY (1) | UY32889A (en) |
WO (1) | WO2011032929A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2493845C1 (en) * | 2012-06-07 | 2013-09-27 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Composition for treating multiple sclerosis (versions) |
US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
WO2017037645A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical formulations of teriflunomide |
WO2017056104A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Limited | Stable pharmaceutical compositions of teriflunomide |
WO2017125841A1 (en) * | 2016-01-20 | 2017-07-27 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of teriflunomide |
WO2018167030A1 (en) | 2017-03-14 | 2018-09-20 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
US11096934B2 (en) | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
WO2022085015A1 (en) * | 2020-10-24 | 2022-04-28 | V-Ensure Pharma Technologies Private Limited | A solid oral composition of teriflunomide |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX336663B (en) * | 2009-09-18 | 2016-01-27 | Sanofi Sa | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)- amide tablet formulations with improved stability. |
AU2014352920A1 (en) * | 2013-11-22 | 2016-06-23 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
CN103656657A (en) * | 2013-12-18 | 2014-03-26 | 北京科源创欣科技有限公司 | Teriflunomide drug composition and preparation method |
HUE053654T2 (en) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
CN114765954B (en) * | 2019-07-17 | 2024-01-02 | 赛特凯恩蒂克公司 | Oral preparation of cardiac sarcomere inhibitor |
GR1010137B (en) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Immediate release solid dosage form comprising teriiflunomide and method of prepeartion thereof |
TR202022336A2 (en) * | 2020-12-30 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A FILM COATED TABLET COMPRISING TERIFLUNOOMIDE |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965276A (en) | 1985-09-27 | 1990-10-23 | Hoechst Aktiengesellschaft | Medicaments to combat chronic graft-versus-host diseases |
US5459163A (en) | 1985-09-27 | 1995-10-17 | Hoechst Aktiengesellschaft | Medicament to combat autoimmune diseases |
US5990141A (en) | 1994-01-07 | 1999-11-23 | Sugen Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
WO2007118684A1 (en) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical compositions containing leflunomid |
EP1381356B1 (en) | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3852294A (en) * | 1968-08-27 | 1974-12-03 | Merck Patent Gmbh | Bis-quaternary pyridinium salts |
US6133301A (en) | 1991-08-22 | 2000-10-17 | Aventis Pharma Deutschland Gmbh | Pharmaceuticals for the treatment of rejection reactions in organ transplantations |
GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
DK0787491T3 (en) | 1994-10-17 | 2000-10-16 | Aventis Pharma Ltd | Remedy for the prevention and treatment of type I allergic diseases |
DE59801792D1 (en) | 1997-08-08 | 2001-11-22 | Aventis Pharma Gmbh | Crystal form of N- (4-trifluoromethylphenyl) -5-methylisoxazole-4-carboxamide |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2001060363A1 (en) | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
US20050158371A1 (en) | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
US20050070608A1 (en) * | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
US20050220874A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist |
SG142305A1 (en) * | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
TWI275029B (en) * | 2005-11-18 | 2007-03-01 | Hon Hai Prec Ind Co Ltd | An embedded system and method for processing data thereof |
PT1810676E (en) | 2006-01-24 | 2009-01-02 | Teva Pharma | Levetiracetam formulations and methods for their manufacture |
EP1990048A3 (en) | 2007-05-08 | 2009-05-06 | Ulrike Wiebelitz | Therapy of benign prostatic hyperplasia (bph) |
MX336663B (en) * | 2009-09-18 | 2016-01-27 | Sanofi Sa | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)- amide tablet formulations with improved stability. |
EP2762135A1 (en) * | 2013-02-04 | 2014-08-06 | Sanofi | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
-
2010
- 2010-09-14 MX MX2012003122A patent/MX336663B/en unknown
- 2010-09-14 AU AU2010297357A patent/AU2010297357B2/en active Active
- 2010-09-14 MY MYPI2012000646A patent/MY155613A/en unknown
- 2010-09-14 JP JP2012529234A patent/JP2013505213A/en not_active Abandoned
- 2010-09-14 UA UAA201204827A patent/UA107582C2/en unknown
- 2010-09-14 EP EP10752585.9A patent/EP2477611B1/en not_active Revoked
- 2010-09-14 US US13/395,586 patent/US20120172427A1/en not_active Abandoned
- 2010-09-14 CN CN201510052300.9A patent/CN104666238B/en not_active Ceased
- 2010-09-14 HU HUE10752585A patent/HUE032963T2/en unknown
- 2010-09-14 LT LTEP10752585.9T patent/LT2477611T/en unknown
- 2010-09-14 RU RU2012115459/15A patent/RU2012115459A/en unknown
- 2010-09-14 PT PT107525859T patent/PT2477611T/en unknown
- 2010-09-14 CR CR20170078A patent/CR20170078A/en unknown
- 2010-09-14 PE PE2012000342A patent/PE20121478A1/en not_active Application Discontinuation
- 2010-09-14 SI SI201031476A patent/SI2477611T1/en unknown
- 2010-09-14 RU RU2015151938A patent/RU2681079C2/en active
- 2010-09-14 CN CN201510052347.5A patent/CN104666272A/en active Pending
- 2010-09-14 WO PCT/EP2010/063439 patent/WO2011032929A1/en active Application Filing
- 2010-09-14 NZ NZ598744A patent/NZ598744A/en unknown
- 2010-09-14 BR BR112012006184-4A patent/BR112012006184B1/en active IP Right Grant
- 2010-09-14 CA CA2772275A patent/CA2772275A1/en not_active Abandoned
- 2010-09-14 UA UAA201409985A patent/UA115979C2/en unknown
- 2010-09-14 ES ES10752585.9T patent/ES2625731T3/en active Active
- 2010-09-14 KR KR1020127006940A patent/KR101547880B1/en active IP Right Grant
- 2010-09-14 PE PE2015002059A patent/PE20152031A1/en active IP Right Grant
- 2010-09-14 RS RS20170589A patent/RS56074B1/en unknown
- 2010-09-14 PL PL10752585T patent/PL2477611T3/en unknown
- 2010-09-14 NZ NZ617025A patent/NZ617025A/en unknown
- 2010-09-14 CN CN201510052299.XA patent/CN104739821B/en not_active Ceased
- 2010-09-14 ME MEP-2017-134A patent/ME02765B/en unknown
- 2010-09-14 CN CN201080041529.8A patent/CN102596184B/en active Active
- 2010-09-14 DK DK10752585.9T patent/DK2477611T3/en active
- 2010-09-16 AR ARP100103381A patent/AR078383A1/en not_active Application Discontinuation
- 2010-09-16 JO JOP/2010/0317A patent/JO3327B1/en active
- 2010-09-16 TW TW99131364A patent/TWI468190B/en active
- 2010-09-16 UY UY0001032889A patent/UY32889A/en not_active Application Discontinuation
- 2010-09-16 TW TW103142089A patent/TWI522130B/en active
-
2012
- 2012-02-10 TN TNP2012000061A patent/TN2012000061A1/en unknown
- 2012-03-05 IL IL218492A patent/IL218492A/en active IP Right Grant
- 2012-03-12 CR CR20120116A patent/CR20120116A/en unknown
- 2012-03-13 MA MA34687A patent/MA33585B1/en unknown
- 2012-03-15 CO CO12045392A patent/CO6511244A2/en active IP Right Grant
- 2012-03-16 DO DO2012000070A patent/DOP2012000070A/en unknown
- 2012-03-16 GT GT201200075A patent/GT201200075A/en unknown
- 2012-03-16 HN HN2012000576A patent/HN2012000576A/en unknown
- 2012-03-16 US US13/422,494 patent/US8802735B2/en active Active
-
2013
- 2013-11-18 AU AU2013257516A patent/AU2013257516B2/en active Active
-
2014
- 2014-04-30 US US14/265,433 patent/US20140235888A1/en not_active Abandoned
-
2015
- 2015-01-08 CL CL2015000047A patent/CL2015000047A1/en unknown
- 2015-07-16 HK HK15106786.8A patent/HK1206245A1/en unknown
- 2015-07-16 HK HK15106785.9A patent/HK1206244A1/en unknown
-
2016
- 2016-03-28 IL IL244809A patent/IL244809B/en active IP Right Grant
- 2016-10-11 US US15/290,677 patent/US20170247319A1/en not_active Abandoned
-
2017
- 2017-06-13 HR HRP20170904TT patent/HRP20170904T1/en unknown
- 2017-07-04 CY CY20171100710T patent/CY1119364T1/en unknown
-
2018
- 2018-08-20 US US15/999,565 patent/US20190241505A1/en not_active Abandoned
-
2019
- 2019-02-19 IL IL26491219A patent/IL264912B/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965276A (en) | 1985-09-27 | 1990-10-23 | Hoechst Aktiengesellschaft | Medicaments to combat chronic graft-versus-host diseases |
US5459163A (en) | 1985-09-27 | 1995-10-17 | Hoechst Aktiengesellschaft | Medicament to combat autoimmune diseases |
US5679709A (en) | 1985-09-27 | 1997-10-21 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases |
US5990141A (en) | 1994-01-07 | 1999-11-23 | Sugen Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
EP1381356B1 (en) | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
WO2007118684A1 (en) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical compositions containing leflunomid |
Non-Patent Citations (7)
Title |
---|
"Remington's Pharmaceutical Sciences, 18th Edition,", 1990, MACK PUBLISHING CO |
BARTLETT R. R. ET AL., AGENT ACTION, vol. 32, no. 1-2, 1991, pages 10 - 21 |
BRUNEAU J-M ET AL., BIOCHEM. J., vol. 36, 1998, pages 299 - 303 |
CHERWINSKI H. M. ET AL., J PHARMACOL. EXP. THER., vol. 272, 1995, pages 460 - 8 |
FUJITA, MEGUMI; UEDA, TOMOHIKO; HANDA, TETSUROU: "Generation of formaldehyde by pharmaceutical excipients and its absorption by meglumine.", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 57, no. 10, 28 July 2009 (2009-07-28), pages 1096 - 1099, XP002566576, DOI: 10.1248/cpb.57.1096 * |
PRKASH A. ET AL., DRUGS, vol. 58, no. 6, 1999, pages 1137 - 66 |
ROWE R C ET AL: "COLLOIDAL SILICON DIOXIDE", 1 January 2006, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, LONDON : PHARMACEUTICAL PRESS.; GB, PAGE(S) 188 - 190, ISBN: 9781582120584, XP003016902 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028308B1 (en) * | 2012-06-07 | 2017-11-30 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Composition for treating multiple sclerosis |
WO2013184023A1 (en) * | 2012-06-07 | 2013-12-12 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Composition for treating multiple sclerosis (variants) |
RU2493845C1 (en) * | 2012-06-07 | 2013-09-27 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Composition for treating multiple sclerosis (versions) |
US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
US11096934B2 (en) | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
WO2017037645A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical formulations of teriflunomide |
WO2017056104A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Limited | Stable pharmaceutical compositions of teriflunomide |
WO2017125841A1 (en) * | 2016-01-20 | 2017-07-27 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of teriflunomide |
WO2018167030A1 (en) | 2017-03-14 | 2018-09-20 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
IL269239B1 (en) * | 2017-03-14 | 2023-03-01 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
IL269239B2 (en) * | 2017-03-14 | 2023-07-01 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
US11723896B2 (en) | 2017-03-14 | 2023-08-15 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
WO2022085015A1 (en) * | 2020-10-24 | 2022-04-28 | V-Ensure Pharma Technologies Private Limited | A solid oral composition of teriflunomide |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013257516B2 (en) | (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | |
JP6173521B2 (en) | Formulations containing nalbuphine and their use | |
US11957791B2 (en) | Methods | |
WO2011010324A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
IL293096A (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
US10583087B2 (en) | Pharmaceutical composition for oral administration | |
KR20210042041A (en) | Phenolamine Form B crystal, production method and composition and use thereof | |
TWI808217B (en) | Composition of fused tricyclic γ-amino acid derivatives and its preparation method | |
US20230098084A1 (en) | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | |
WO2014157603A1 (en) | Pharmaceutical composition for oral administration | |
KR20220062049A (en) | Pharmaceutical formulations of indoleamine 2,3-dioxygenase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080041529.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10752585 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12012500314 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2772275 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218492 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13395586 Country of ref document: US Ref document number: CR2012-000116 Country of ref document: CR |
|
REEP | Request for entry into the european phase |
Ref document number: 2010752585 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010297357 Country of ref document: AU Ref document number: MX/A/2012/003122 Country of ref document: MX Ref document number: 2010752585 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12045392 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 0152512 Country of ref document: KE Ref document number: 20127006940 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012529234 Country of ref document: JP Ref document number: 2435/CHENP/2012 Country of ref document: IN Ref document number: 000342-2012 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201001209 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010297357 Country of ref document: AU Date of ref document: 20100914 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201204827 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012115459 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006184 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002059-2015 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 244809 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 112012006184 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120319 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201778 Country of ref document: CR Ref document number: CR2017-000078 Country of ref document: CR |